首页|University of Paris Descartes Reports Findings in Prostatectomy (Urinary symptoms change and quality of life after robotic radical prostatectomy: a secondary analysis of a randomized controlled trial)
University of Paris Descartes Reports Findings in Prostatectomy (Urinary symptoms change and quality of life after robotic radical prostatectomy: a secondary analysis of a randomized controlled trial)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
New research on Surgery - Prostatectomy is the subject of a report. According to news reporting originating from Paris, France, by NewsRx correspondents, research stated, “To present the patient-reported QoL outcomes from a prospective, randomized controlled trial comparing the use of pelvic floor muscle training (PFMT) and duloxetine after robot-assisted radical prostatectomy (RARP). We identified 213 men with organ-confined disease having post-RARP urinary incontinence who were randomly assigned to received PFMT, duloxetine, combined PFMT-duloxetine and pelvic floor muscle home exercises.” Our news editors obtained a quote from the research from the University of Paris Descartes, “Urinary symptoms burden was measured by marked clinical important difference improvement (MCID) defined by using the International Prostate Symptom Score(IPSS) difference of -8 points(DIPSS -8). QoL was assessed according to Visual Analog Scale(VAS), King’s Health Questionnaire(KQH), and International Index of Erectile Function(IIEF-5). Multivariable regression analyses aimed to predict MCID, burden of urinary symptoms (IPSS 8), and patients reporting to be satisfied (IPSS QoL 2) or comfortable (VAS 1) post-RARP. Moderate to severe urinary symptoms decreased from 48% pre-operatively to 40%, 34% and 23% at 3mo, 6mo and 12mo post-RARP. After surgery, MCID improvement was observed in 19% of patients, and deterioration in 3.3%. Large prostate was the only factor associated to MCID (OR 1.03 [95%CI 1.01-1.05], p=0.005). At 6mo, patients reached the same degree of preoperative satisfaction. NVB preservation was the only predictor of being comfortable regarding urinary symptoms postoperatively (OR12.8 [CI95% 1.47-111.7],P=0.02 at 3mo) and was also associated to higher median postoperative IIEF-5. Despite UI following RARP, patients with larger prostates experience a reduction of lower urinary tract symptoms (LUTS) within a year, which subsequently elevates QoL.”
ParisFranceEuropeClinical ResearchClinical Trials and StudiesEmerging TechnologiesHealth and MedicineMachine LearningMale Urologic Surgical ProceduresMen’s HealthProstatectomyQuality of LifeRoboticsRobotsSurgery
NETL
NSTL
